• The BACE inhibitor verubecestat (MK-8931) demonstrated cognitive and functional decline relative to placebo in a 2-year Phase 3 trial of individuals with prodromal AD (APECS; NCT01953601), along with reductions in brain volume and amyloid plaque. Disease progression modeling has demonstrated a lack of dose or exposure dependency in the clinical cognition and function endpoints (see Poster# P1-044)
• In this analysis, pharmacokinetic (PK), safety, and biomarker data from the trial were examined to characterize target engagement and biomarker exposure-response
The Alzheimers Association International Conference (AAIC); July 14-18, 2019; Los Angeles, CA.
By J Stone, H Kleijn, David Jaworowicz, Julie Passarell, M Dockendorf, M Xu, C Rasmussen, Rebecca Humphrey, T Voss, M Egan.